Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Institute of Oncology Prof. Dr. Ion Chiricuta · Instituto Nacional de Cancerología · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,304
total citations
- FWCI
- 105.92
- Percentile
- 100%
- References
- 35
Citations per year
Authors
26Topics & keywords
Topics
Keywords
- Docetaxel
- Ramucirumab
- Medicine
- Internal medicine
- Hazard ratio
- Regimen
- Lung cancer
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.